| Trial ID # | NCT02799095; ARTISTRY-1 |
| Phase | I/II |
| Drug Class | Immunotherapy: Immune Cell Stimulators/IL-2R |
| Drug Name | Nemvaleukin alfa |
| Alternate Drug Names | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 |
| Drugs in Trial | Nemvaleukin alfa, Pembrolizumab |
| Eligible Participant | Advanced solid tumors |
| Patients Enrolled | 16; median 5 prior therapies (2-6); 60% w/ prior Bev, 20% with prior checkpoint inhibitor therapy |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, evaluated per RECIST |
| Efficacy | Nem: 36 patients, median 3 prior therapies (1-8), 1 ovarian Nem+Pem: 15 ovarian, median 5 prior therapies (2-6), 14 evaluable |
| Conclusion | Nemvaleukin alfa (ALKS 4230) alone and with pembrolizumab is well tolerated with encouraging clinical benefit |
| Reference | Boni V et al. ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors. J Clin Oncol (2021) 39 (suppl 15; abstr 2513) Boni V et al. Poster Slide from SGO 2022 presentation; scientific plenary III, abstract 229 Vaishampayan UN et al. Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. J Clin Oncol 40, 2022 (suppl 16; abstr 2500) Vaishampayan UN et al. Slide from presentation |